Perceptic, a startup automating drug discovery end-to-end for Big Pharma, has officially emerged from stealth, announcing a significant $12 million seed funding round on May 26, 2026. This substantial investment, led by London-based venture capital firm Accel, with participation from Air Street Capital and Elder Gull, signals a potent belief in Perceptic’s innovative approach to revolutionizing pharmaceutical R&D.
The company, founded by a formidable trio of former Palantir executives—Tilman Flock, Martin Copes, and Zaki Trache—aims to address a critical bottleneck in the drug development lifecycle. These founders previously played pivotal roles in building Palantir’s Life Sciences practice, bringing a wealth of experience in commercial AI platforms and their application within complex scientific domains. Their new venture, Perceptic, is not merely another AI tool for a specific part of drug development; it positions itself as the ‘connective tissue’ that unifies disparate AI models and proprietary data across the entire drug discovery process, from initial research to clinical trial design.
The Strategy Behind Automating Drug Discovery
Perceptic’s core strategy centers on creating an infrastructure and model-agnostic platform that allows pharmaceutical companies to integrate their own data, hardware, and AI models seamlessly. Tilman Flock, Perceptic’s cofounder and CEO, emphasizes that while many AI startups focus on isolated improvements—such as predicting protein structures or optimizing patient recruitment—Perceptic’s strength lies in its holistic, end-to-end vision. Flock notes that the traditional, linear approach to drug discovery often leads to ‘insight dying at every handoff,’ a critical inefficiency that Perceptic seeks to eliminate.
The company is targeting three crucial areas of pharma R&D. First, it streamlines the scouting of external assets from biotechnology companies, compressing scientific due diligence from weeks to mere hours. This capability is invaluable for large pharmaceutical firms looking to license promising drug candidates. Second, Perceptic assists in the high-stakes decision of choosing clinical trial indications, a choice that can dictate the success or failure of multi-million-dollar investments. Finally, the platform builds a robust ‘data foundation’ for clinical trial design, which has already demonstrated a remarkable 50-fold increase in clinical data extractions for its early adopters.
Sonali De Rycker, the Accel partner who spearheaded the investment, highlighted the platform’s ability to ‘follow the drug’ through its entire development lifecycle. She underscored the illogical nature of siloed departmental operations within drug development, from initial hypothesis to clinical trial design, and praised Perceptic’s unified approach. Accel had been tracking Flock, Copes, and Trache during their tenure at Palantir, noting their significant contributions to AIP. The investment materialized approximately a year after their initial meeting, following Perceptic’s successful transition from pilot programs to paid production deployments with top-tier pharmaceutical companies, including Australian biotechnology firm CSL.
“From the point at which you have hypothesis and evidence all the way to when you’re designing the clinical trial, and everything you do in between … it makes no sense for it to be siloed,” De Rycker stated, explaining Accel’s conviction in Perceptic’s strategy.
Company Background and Competitive Edge
The founders’ deep roots in Palantir, a company renowned for its complex data integration and analysis platforms, provide Perceptic with a significant competitive advantage. Their experience in building commercial AI platforms for life sciences companies has directly informed Perceptic’s architecture. The startup, currently boasting a team of around 20 employees, primarily bases its engineering operations in London, drawing on a pool of talent that includes many Palantir alumni.
Perceptic’s platform is designed to harmonize three distinct categories of data: public knowledge (patents, literature), internal proprietary data accumulated over years of research, and external datasets from consultants and vendors. This comprehensive data integration is crucial for pharmaceutical companies, which require a clear provenance for any data used in decision-making. Flock stresses that Perceptic’s AI system is built to prevent ‘hallucinations’—where AI models invent or conflate information—by allowing customers to trace every claim back to its original source. This commitment to data integrity is paramount in the highly regulated pharmaceutical industry.
The landscape of AI in drug discovery is competitive, with numerous startups like Isomorphic (a Google DeepMind spin-out), Recursion, and Insilico Medicine vying for market share. However, Perceptic distinguishes itself by offering an overarching operating system rather than a niche tool. Nathan Benaich, founder and general partner of Air Street Capital, affirmed this perspective, stating that pharma’s next R&D leap ‘won’t come from a thousand better point tools, or from frontier models alone’ but from a system that connects data, decisions, and context across the arduous 15-year drug development process.
Market Impact and Future Outlook
Perceptic’s emergence and substantial seed funding round signal a significant shift in how Big Pharma might approach drug discovery. By providing an integrated, end-to-end platform, the company promises to accelerate development timelines, reduce costs, and ultimately bring life-saving drugs to market faster. This could have profound implications for an industry where the average drug takes over a decade and billions of dollars to develop, with a high rate of failure in clinical trials.
The market is increasingly recognizing the potential of enterprise AI platforms that unify workflows across multiple departments. Sonali De Rycker views Perceptic’s approach as reflective of this broader trend, where such platforms can become ‘almost a new source of truth,’ potentially supplanting traditional databases and enterprise resource planning software. Given Europe’s concentration of pharmaceutical talent in regions like Switzerland and the U.K., De Rycker believes Perceptic has a ‘right to win’ from its London base, even as it plans to expand its presence in the United States to serve its growing customer base.
With the $12 million seed capital, Perceptic plans to heavily invest in engineering and expand its customer acquisition efforts. Flock confidently asserts, “We’re far beyond product-market fit. It’s about scaling out.” This aggressive growth strategy, coupled with a proven team and a unique value proposition, positions Perceptic as a formidable player in the burgeoning field of AI-driven pharmaceutical innovation. The company’s ability to deliver on its promise of automating drug discovery could redefine the future of medicine, offering a blueprint for more efficient and effective therapeutic development.
